Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria

作者: Andre Arizpe , Kelly R. Reveles , Shrina D. Patel , Samuel L. Aitken

DOI: 10.1007/S11908-016-0552-7

关键词: Gram-negative bacteriaPiperacillin/tazobactamCarbapenemCephalosporinAntimicrobialIntensive care medicineCeftazidime/avibactamCefepimeMicrobiologyMedicinePseudomonas aeruginosa

摘要: Resistance to cephalosporins is now common among Gram-negative bacterial infections, including those caused by the Enterobacteriaceae and Pseudomonas aeruginosa, posing a major threat public health. As resistance traditional drugs of choice for these carbapenems, has also become increasingly common, interest in cefepime piperacillin-tazobactam as carbapenem-sparing alternatives increased. Additionally, availability novel β-lactam-β-lactamase inhibitor combinations ceftolozane-tazobactam ceftazidime-avibactam added antimicrobial armamentarium available treat multidrug-resistant infections. Here, we review recent literature on use highlight potential utility antimicrobials.

参考文章(101)
Qianqian Liu, Xiaoqing Li, Wenzhang Li, Xinmiao Du, Jian-Qing He, Chuanmin Tao, Yulin Feng, Influence of carbapenem resistance on mortality of patients with Pseudomonas aeruginosa infection: a meta-analysis Scientific Reports. ,vol. 5, pp. 11715- 11715 ,(2015) , 10.1038/SREP11715
Jonathan C. Cho, Mallory A. Fiorenza, Sandy J. Estrada, Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. ,vol. 35, pp. 701- 715 ,(2015) , 10.1002/PHAR.1609
Helio S. Sader, Mariana Castanheira, Rodrigo E. Mendes, Robert K. Flamm, David J. Farrell, Ronald N. Jones, Ceftazidime-Avibactam Activity against Multidrug-Resistant Pseudomonas aeruginosa Isolated in U.S. Medical Centers in 2012 and 2013 Antimicrobial Agents and Chemotherapy. ,vol. 59, pp. 3656- 3659 ,(2015) , 10.1128/AAC.05024-14
B. A. Evans, S. G. B. Amyes, OXA β-Lactamases Clinical Microbiology Reviews. ,vol. 27, pp. 241- 263 ,(2014) , 10.1128/CMR.00117-13
Y. Harada, Y. Morinaga, N. Kaku, S. Nakamura, N. Uno, H. Hasegawa, K. Izumikawa, S. Kohno, K. Yanagihara, In vitro and in vivo activities of piperacillin‐tazobactam and meropenem at different inoculum sizes of ESBL‐producing Klebsiella pneumoniae Clinical Microbiology and Infection. ,vol. 20, ,(2014) , 10.1111/1469-0691.12677
Sarah M. Drawz, Robert A. Bonomo, Three Decades of β-Lactamase Inhibitors Clinical Microbiology Reviews. ,vol. 23, pp. 160- 201 ,(2010) , 10.1128/CMR.00037-09
Andrea Endimiani, Federico Perez, Robert A Bonomo, Cefepime: a reappraisal in an era of increasing antimicrobial resistance Expert Review of Anti-infective Therapy. ,vol. 6, pp. 805- 824 ,(2008) , 10.1586/14787210.6.6.805
Matthew E. Falagas, Giannoula S. Tansarli, Petros I. Rafailidis, Anastasios Kapaskelis, Konstantinos Z. Vardakas, Impact of Antibiotic MIC on Infection Outcome in Patients with Susceptible Gram-Negative Bacteria: a Systematic Review and Meta-Analysis Antimicrobial Agents and Chemotherapy. ,vol. 56, pp. 4214- 4222 ,(2012) , 10.1128/AAC.00663-12
David J. Farrell, Robert K. Flamm, Helio S. Sader, Ronald N. Jones, Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012) Antimicrobial Agents and Chemotherapy. ,vol. 57, pp. 6305- 6310 ,(2013) , 10.1128/AAC.01802-13